Linkage to care is a crucial early step in successful HIV treatment and is typically defined as the completion of a first medical clinic visit after an HIV diagnosis. Linkage to care plays a key early role in the HIV care continuum, as a necessary precursor to antiretroviral therapy initiation and viral suppression (Figure 1). Antiretroviral therapy significantly reduces the risk of developing HIV-related complications and dramatically reduces HIV transmission to others.[1,2,3,4] Without timely entry into care, individuals with HIV miss an opportunity to benefit from HIV treatment at the earliest stage feasible.[5,6]
Goals for Linkage to Care
Linkage to care and rapid initiation of antiretroviral therapy after HIV diagnosis is a key pillar of the national initiative, Ending the HIV Epidemic: A Plan for America.[7,8] The Ending the HIV Epidemic has a goal for persons newly diagnosed with HIV to increase linkage to HIV medical care to 95% by the year 2025.[8,9] In addition, the Adult and Adolescent ARV Guidelines recommend rapid initiation of antiretroviral therapy for persons newly diagnosed with HIV, ideally on the same day of the HIV diagnosis.[10] Identifying persons with HIV and successfully linking them to care plays a key role in addressing the HIV epidemic, both from a treatment and a prevention standpoint (Figure 2). The following provides a review of the current state of linkage to care in the United States, examines the major barriers to linkage to care, and explores strategies to improve linkage to care.
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant